Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma

Clinical Trial ID NCT03013101

Rank	Title	Journal	Year	PubWeight™‹?›
1	Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.	N Engl J Med	2012	52.99
2	Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.	J Clin Oncol	2014	9.86